Global Pulmonary Arterial Hypertension Market 2028
“Pulmonary Arterial Hypertension Market” study by “The Insight Partners” provides details about the market dynamics affecting the market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favorable competitive landscape and trends prevailing over the years.
For Sample Report Click: - https://www.theinsightpartners.com/sample/TIPRE00005221/
Companies Mentioned: Johnson & Johnson,Gilead Sciences Inc,United Therapeutics Corp,Bayer AG,Aerami Therapeutics Holdings Inc,Novartis AG,GSK Plc,Teva Pharmaceutical Industries Ltd,Lupin Ltd,Pfizer Inc.
In pulmonary arterial hypertension (PAH), tiny arteries in lung become thick and narrow. PAH blocks the blood flow through lungs. As a result, blood pressure in the lungs increases, and heart faces difficulties to pump blood through narrowed arteries. Over the time, an individual's heart loses the ability to pump blood throughout the body effectively. PAH usually affects women in the age range from 30 to 60 years. National Organization for Rare Disorders (NORD) stated that the cases of PAH are 3–5 times higher in females than in males. Also, in the US, new cases are projected to occur in one to two people per million per year. The incidence is projected to be the same in Europe. About 500–1,000 new cases of PAH are diagnosed annually in the US.
The pulmonary arterial hypertension market is segmented on the basis of drug, type, route of administration, distribution channel, and geography. Based on drug, the pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. In 2021, prostacyclin and prostacyclin analogs are likely to account for the largest share of the market and the same segment is also anticipated to register the highest CAGR of 6.6% in the market during the forecast period. The factor driving the prostacyclin and prostacyclin analogs segment mainly include the use of PAH prostacyclin analogs as medications to treat pulmonary arterial hypertension (PAH), a condition of high blood pressure in the arteries that carry deoxygenated blood from the heart to the lungs.
Key Elements that the report acknowledges:
Market size and growth rate during forecast period.
Key factors driving the “Pulmonary Arterial Hypertension market” market.
Key market trends cracking up the growth of the “Pulmonary Arterial Hypertension market” market.
Challenges to market growth.
Key vendors of “Pulmonary Arterial Hypertension market” market.
Detailed SWOT analysis.
Opportunities and threats faces by the existing vendors in Global “Pulmonary Arterial Hypertension ” market.
Trending factors influencing the market in the geographical regions.
Strategic initiatives focusing the leading vendors.
PEST analysis of the market in the five major regions.
About The Insight Partners:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi E-mail: sales@theinsightpartners.com Phone: +1-646-491-9876